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background: Right-sided heart failure is an important cause of morbidity in rheumatic mitral stenosis (MS), and attributed mainly to pulmonary 
hypertension. Percutaneous mitral valvuloplasty (PMV) effectively reduces pulmonary artery pressure (PAP) but its influence on RV function is unclear. 
This study evaluated the immediate effects of the PMV on RV function. In addition we sought to identify the determinants of the RV function post 
PMV and the impact of RV function post PMV on long-term clinical outcome.
methods: Patients with symptomatic MS who underwent PMV (2000-2013) at 2 centers were recruited. A range of invasive hemodynamic and 
echocardiographic measures (pre and 24 hours post PMV) were collected. RV function was assessed by RV fractional area change (RVFAC). Long-
term outcome was a composite endpoint of death, mitral valve (MV) replacement or repeat PMV.
results: A total of 337 patients (mean age 51 ± 16 years, 285 women) were examined. PAP decreased from 38 ± 11 to 32 ± 12 mmHg (p<0.001) 
while RVFAC increased from 43.7% ± 0.11 to 48.4% ± 0.09 (p<0.001) immediately after PMV, with a weak correlation between changes in mean 
PAP and RVFAC (r=0.3; p=0.009). By multivariable linear regression analysis, the variables associated with RVFAC post PMV were NYHA functional 
class (p=0.026), mitral valve area pre PMV (p=0.017), and post-procedural mean gradient (p=0.037), and the severity of tricuspid regurgitation 
(p=0.021). During a mean follow-up of 26 (0-148) months, 84 adverse clinical events were observed (31 deaths, 41 MV replacements, and 12 
repeated PMV). RVFAC post PMV was associated with an adverse outcome (HR 0.72, 95% CI 0.57-0.90; p=0.004). However, neither RVFAC post PMV 
or change in RVFAC was an independent predictor of long-term event-free survival, after adjustment for post procedure hemodynamic data.
conclusions: In the setting of severe MS, RV function improved post PMV and were associated with parameters that express MS severity including 
NYHA functional class and mitral valve area, in addition to post procedural mean gradient and the severity of tricuspid regurgitation. RV function 
immediately post PMV did not predict long term adverse outcome.
